Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Return on Sales (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Return on Sales for 15 consecutive years, with 0.25% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales rose 13.0% to 0.25% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.12%, a 72.0% increase, with the full-year FY2024 number at 0.09%, up 85.0% from a year prior.
  • Return on Sales was 0.25% for Q3 2025 at Gyre Therapeutics, up from 0.08% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 3.7% in Q3 2022 to a low of 18.31% in Q1 2022.
  • A 5-year average of 3.72% and a median of 0.07% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: crashed -1504bps in 2021, then skyrocketed 1824bps in 2023.
  • Gyre Therapeutics' Return on Sales stood at 8.49% in 2021, then skyrocketed by 97bps to 0.28% in 2022, then crashed by -961bps to 3.01% in 2023, then surged by 99bps to 0.02% in 2024, then soared by 1388bps to 0.25% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Return on Sales are 0.25% (Q3 2025), 0.08% (Q2 2025), and 0.17% (Q1 2025).